產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-PKA C alpha+beta抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-PKA C alpha+beta抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-PKA C alpha+beta
Cat. Number:
Anti-PKA C alpha+beta抗體KL-2371R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP dependent protein kinase (AMPK), which transduces the signal through phosphorylation of different Anti-PKA C alpha+beta抗體target proteins. The inactive holoenzyme of AMPK is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits of AMPK have been identified in humans. PKA beta (catalytic subunit) is a member of the Ser/Thr protein kinase family and is a catalytic subunit of AMPK.
Also known as:
PKA C beta; PKACB; KAPCB_HUMAN; Anti-PKA C alpha+beta抗體PRKACB; Protein kinase cAMP dependent catalytic beta; KAPCA_HUMAN; KAPCA_HUMAN; cAMP-dependent protein kinase catalytic subunit alpha; PKA C-alpha.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Anti-PKA C alpha+beta抗體Chicken, Dog, Pig, Cow, .
●
Immunogen: KLH conjugated synthetic peptide derived from human PKA beta.
●
Predicted Molecular Weight: 40,50kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-PKA C alpha+beta抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-PKA C alpha+beta抗體
Optimal working dilutions must be determined by the end user.
